<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401685</url>
  </required_header>
  <id_info>
    <org_study_id>RD-5103-001-13</org_study_id>
    <secondary_id>ISRCTN Number</secondary_id>
    <nct_id>NCT02401685</nct_id>
  </id_info>
  <brief_title>POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer</brief_title>
  <acronym>POSNOC</acronym>
  <official_title>POSNOC - POsitive Sentinel NOde: Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance or Axillary Radiotherapy. A Randomised Controlled Trial of Axillary Treatment in Women With Early Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals of Derby and Burton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sussex Health Outcomes Research &amp; Education in Cancer (SHORE-C)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCRI Radiotherapy Trials QA Group (RTTQA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Trials, Australia and New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals of Derby and Burton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      POSNOC is a pragmatic, randomised, multicentre, non-inferiority trial.&#xD;
&#xD;
      Aim For women with early stage breast cancer and one or two sentinel node macrometastases, to&#xD;
      assess whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary&#xD;
      treatment, in terms of axillary recurrence within 5 years.&#xD;
&#xD;
      Stratification: Institution, Age (&lt;50, ≥50), Breast-conserving surgery (BCS) or mastectomy,&#xD;
      Estrogen receptor (ER) status (positive, negative), Number of positive nodes (1, 2),&#xD;
      Intra-operative sentinel assessment using OSNA (yes, no).&#xD;
&#xD;
      Interventions The study will compare adjuvant therapy alone with adjuvant therapy plus&#xD;
      axillary treatment (axillary node clearance (ANC) or axillary radiotherapy (ART)).&#xD;
&#xD;
      Sample Size: 1900 participants&#xD;
&#xD;
      Follow-up: Participants will be followed up for 5 years.&#xD;
&#xD;
      Adjuvant Therapy: All participants will receive adjuvant systemic therapy (chemotherapy&#xD;
      and/or endocrine therapy). All participants may receive breast/chest wall radiotherapy.&#xD;
      Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to adjuvant&#xD;
      therapy alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axillary recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Axillary recurrence is defined as pathologically (cytology or biopsy) confirmed recurrence in lymph nodes draining the primary tumour site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm morbidity</measure>
    <time_frame>3 years</time_frame>
    <description>Arm morbidity will be assessed by the Lymphoedema and Breast Cancer and QuickDASH (disabilities of the arm, shoulder and hand) questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast+4 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety (Spielberger State/Trait Anxiety Inventory)</measure>
    <time_frame>3 years</time_frame>
    <description>Anxiety will be assessed with the Spielberger State/Trait Anxiety Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation (EQ-5D-5L (EuroQoL)</measure>
    <time_frame>3 years</time_frame>
    <description>Health-related quality of life will be evaluated using the EQ-5D-5L (EuroQoL) instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local (breast or chest wall) recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with local (breast or chest wall) recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional (nodal) recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with regional (nodal) recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to axillary recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contralateral breast cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with contralateral breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-breast malignancy</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with non-breast malignancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1900</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant therapy plus axillary treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adjuvant therapy</intervention_name>
    <description>Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.</description>
    <arm_group_label>Adjuvant therapy alone</arm_group_label>
    <arm_group_label>Adjuvant therapy plus axillary treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary treatment</intervention_name>
    <description>Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.</description>
    <arm_group_label>Adjuvant therapy plus axillary treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unifocal or multi-focal invasive tumour with lesion ≤5 cm in its largest dimension,&#xD;
             measured pathologically or largest invasive tumour diameter on radiology should be&#xD;
             used for women who are randomised intra-operatively or undergo sentinel node biopsy&#xD;
             before neoadjuvant therapy (tumour size should be based only on the single largest&#xD;
             tumour; do not add the sizes together from the multiple foci)&#xD;
&#xD;
          -  At sentinel node biopsy have 1 or 2 nodes with macrometastases (tumour deposit &gt;2.0mm&#xD;
             in largest dimension or defined as macrometastasis on molecular assay)&#xD;
&#xD;
          -  Fit for axillary treatment and adjuvant therapy&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bilateral invasive breast cancer&#xD;
&#xD;
          -  more than 2 nodes with macrometastases&#xD;
&#xD;
          -  neoadjuvant therapy for breast cancer except:&#xD;
&#xD;
               -  if sentinel node biopsy performed prior to neoadjuvant chemotherapy in women with&#xD;
                  early breast cancer&#xD;
&#xD;
               -  short duration of neoadjuvant endocrine therapy is acceptable (up to 3 months)&#xD;
&#xD;
          -  previous axillary surgery on the same body side as the scheduled sentinel node biopsy&#xD;
&#xD;
          -  not receiving adjuvant systemic therapy&#xD;
&#xD;
          -  previous cancer less than 5 years previously or concomitant malignancy except:&#xD;
&#xD;
               -  basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  in situ carcinoma of the cervix&#xD;
&#xD;
               -  in situ melanoma&#xD;
&#xD;
               -  contra- or ipsilateral in situ breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Goyal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Derby and Burton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcocombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maeter Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne and Royal Women's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverina Cancer Care Centre</name>
      <address>
        <city>Wagga Wagga</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotorua Hospital</name>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford and St Peter's Hospitals NHS Foundation Trust</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bolton Hospital</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess of Wales Hospital</name>
      <address>
        <city>Bridgend</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Llandough</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darrent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inverclyde Royal Hospital</name>
      <address>
        <city>Greenock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Crosshouse</name>
      <address>
        <city>Kilmarnock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forth Valley Hospital</name>
      <address>
        <city>Larbert</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luton and Dunstable University Hospital</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macclesfield District General Hospital</name>
      <address>
        <city>Macclesfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotherham General Hospital</name>
      <address>
        <city>Rotherham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wishaw General Hospital</name>
      <address>
        <city>Wishaw</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.posnoc.co.uk</url>
    <description>Trial website</description>
  </link>
  <link>
    <url>http://twitter.com/posnoc?lang=en</url>
    <description>@POSNOC</description>
  </link>
  <link>
    <url>https://www.thelancet.com/protocol-reviews/14PRT-0519</url>
    <description>Protocol summary</description>
  </link>
  <reference>
    <citation>Goyal A, Dodwell D. POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases. Clin Oncol (R Coll Radiol). 2015 Dec;27(12):692-5. doi: 10.1016/j.clon.2015.07.005. Epub 2015 Aug 5.</citation>
    <PMID>26254841</PMID>
  </reference>
  <reference>
    <citation>Dodwell D, Goyal A. Axillary conservation in early breast cancer. Br J Surg. 2015 Oct;102(11):1297-9. doi: 10.1002/bjs.9881. Epub 2015 Jul 7.</citation>
    <PMID>26148870</PMID>
  </reference>
  <reference>
    <citation>Goyal A, Dodwell D, Reed MW, Coleman RE. Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice. J Clin Oncol. 2014 Dec 1;32(34):3902. doi: 10.1200/JCO.2014.57.3717. Epub 2014 Sep 22.</citation>
    <PMID>25245444</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals of Derby and Burton NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Amit Goyal</investigator_full_name>
    <investigator_title>Consultant Oncoplastic Breast Surgeon &amp; Associate Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>sentinel lymph node biopsy</keyword>
  <keyword>axillary lymph node clearance</keyword>
  <keyword>axillary lymph node dissection</keyword>
  <keyword>macrometastases</keyword>
  <keyword>axillary radiotherapy</keyword>
  <keyword>POSNOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

